Early Mixed Chimerism-based Preemptive Immunotherapy in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2017 Feb 17

PMID 28205327

Citations 2

Authors

Biljana Horn

Justin T Wahlstrom

Alexis Melton

Angela Liou

Marie Ouachee-Chardin

Gauri Sunkersett

Jennifer Willert

Jimmy Hwang

Jueleah Expose-Spencer

Mort C Cowan

Janelle Facchino

Christopher C Dvorak

Affiliations

Soon will be listed here.

Abstract

This retrospective analysis comprises 10-year experience with early posttransplant mixed chimerism-based preemptive intervention. Out of 104 patients, 51 received preemptive immunotherapy. Their outcomes were similar to patients achieving full donor chimerism spontaneously. Among patients receiving intervention, 5-year event-free survival was identical in patients with and without pretransplant residual disease, respectively (68% [95% confidence interval (CI) 38-98%] vs. 69% [95% CI 54-85%] log-rank = 0.4). In patients who received preemptive immunotherapy, chimerism status and residual disease prior to transplant were no longer predictors of poor outcome; however, 41% of the patients with residual disease prior to transplant relapsed early and did not benefit from this strategy.

Citing Articles

Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application.

Navarro-Bailon A, Carbonell D, Escudero A, Chicano M, Muniz P, Suarez-Gonzalez J Genes (Basel). 2020; 11(9).

PMID: 32854376 PMC: 7565503. DOI: 10.3390/genes11090993.

Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.

Lejman M, Zaucha-Prazmo A, Zawitkowska J, Mroczkowska A, Grabowski D, Kowalczyk J BMC Cancer. 2019; 19(1):1141.

PMID: 31771553 PMC: 6878687. DOI: 10.1186/s12885-019-6360-3.

References

Yan C, Liu D, Liu K, Xu L, Liu Y, Chen H . Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012; 119(14):3256-62. DOI: 10.1182/blood-2011-09-380386. View

Lankester A, Bierings M, van Wering E, Wijkhuijs A, de Weger R, Wijnen J . Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010; 24(8):1462-9. DOI: 10.1038/leu.2010.133. View

Rettinger E, Willasch A, Kreyenberg H, Borkhardt A, Holter W, Kremens B . Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood. 2011; 118(20):5681-8. DOI: 10.1182/blood-2011-04-348805. View

Terwey T, Hemmati P, Nagy M, Pfeifer H, Gokbuget N, Bruggemann M . Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014; 20(10):1522-9. DOI: 10.1016/j.bbmt.2014.05.026. View

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M . Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant. 2008; 43(6):469-76. DOI: 10.1038/bmt.2008.339. View

Tracey J, Zhang M, Thiel E, Sobocinski K, Eapen M . Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012; 19(2):255-9. PMC: 3553255. DOI: 10.1016/j.bbmt.2012.09.019. View

Zeiser R, Spyridonidis A, Wasch R, Ihorst G, Grullich C, Bertz H . Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2005; 19(5):814-21. DOI: 10.1038/sj.leu.2403719. View

Bitan M, He W, Zhang M, Abdel-Azim H, Ayas M, Bielorai B . Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014; 123(10):1615-20. PMC: 3945869. DOI: 10.1182/blood-2013-10-535716. View

10.

di Grazia C, Pozzi S, Geroldi S, Grasso R, Miglino M, Colombo N . Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(7):1242-1246. DOI: 10.1016/j.bbmt.2016.03.005. View

11.

Pulsipher M, Carlson C, Langholz B, Wall D, Schultz K, Bunin N . IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015; 125(22):3501-8. PMC: 4447864. DOI: 10.1182/blood-2014-12-615757. View

12.

Walter R, Buckley S, Pagel J, Wood B, Storer B, Sandmaier B . Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013; 122(10):1813-21. PMC: 3765060. DOI: 10.1182/blood-2013-06-506725. View

13.

Balduzzi A, Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A . Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. Br J Haematol. 2014; 164(3):396-408. DOI: 10.1111/bjh.12639. View

14.

Rujkijyanont P, Morris C, Kang G, Gan K, Hartford C, Triplett B . Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J. 2013; 3:e137. PMC: 3763390. DOI: 10.1038/bcj.2013.39. View

15.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

16.

Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P . Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol. 2004; 22(9):1696-705. DOI: 10.1200/JCO.2004.05.198. View

17.

Horn B, Petrovic A, Wahlstrom J, Dvorak C, Kong D, Hwang J . Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies. Biol Blood Marrow Transplant. 2015; 21(4):729-37. DOI: 10.1016/j.bbmt.2014.12.029. View

18.

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View